MP61-15 USE OF A NOVEL NEAR-INFRARED IMAGING AGENT FOR INTRA-OPERATIVE PROSTATE CANCER DETECTION

You have accessJournal of UrologyProstate Cancer: Basic Research IV1 Apr 2015MP61-15 USE OF A NOVEL NEAR-INFRARED IMAGING AGENT FOR INTRA-OPERATIVE PROSTATE CANCER DETECTION Jonathan E. Kiechle, Xinning Wang, Shan Dong, Steve S. Huang, Warren D.W. Heston, Lee E. Ponsky, and James P. Basilion Jonathan E. KiechleJonathan E. Kiechle More articles by this author , Xinning WangXinning Wang More articles by this author , Shan DongShan Dong More articles by this author , Steve S. HuangSteve S. Huang More articles by this author , Warren D.W. HestonWarren D.W. Heston More articles by this author , Lee E. PonskyLee E. Ponsky More articles by this author , and James P. BasilionJames P. Basilion More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.2196AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Prostate cancer (PCa) is the most common noncutaneous malignancy affecting men in the United States. In the era of prostate specific antigen screening, a majority of men are diagnosed with clinically localized disease. Unfortunately, microscopic extra-capsular extension is currently not able to be determined at time of surgery. Real-time, intra-operative determination of PCa extension would allow surgeons to maximize negative margin rates while limiting unnecessarily wide resections. The purpose of this study was to develop a targeted near- infrared (NIR) optical imaging probe for intraoperative visualization of prostate cancer. METHODS Prostate specific membrane antigen (PSMA) is over-expressed in prostate cancer. We synthesized a high- affinity PSMA ligand (PSMA-1) with low molecular weight and further labeled it with commercially available NIR dyes IRDy800 and Cy5.5. Mice were implanted with either heterotopic or orthotopic prostate tumors and then injected via the tail vein with high affinity PSMA-targeted NIR probes. Probe fluorescence was detected using the Maestro Imaging System (Perkin-Elmer) or, for image guided surgical resection, a Spy2000 Imaging system (Novadaq, Inc). Following imaging, mice were sacrificed and tumors were harvested for ex-vivo imaging RESULTS Selective binding was measured for each of the probes, in both in vitro and in vivo studies, using competitive binding and uptake studies. Interestingly, the results indicated that the pharmacokinetics of the probes were dependent on the fluorophore conjugated to the PSMA-1 ligand and varied widely. Either agent was selectively retained in PSMA-expressing tumors and could be used to guide removal. Real-time imaging using the Spy2000 allowed for complete resection of orthotopically placed tumors with resection confirmed using the Maestro system. CONCLUSIONS The PSMA-IR probes can distinguish between PSMA-expressing and non-expressing tumors or normal tissues. These data suggest that PSMA-targeted probes have the potential to be further developed as contrast agents for clinical intraoperative fluorescence-guided surgery. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e752 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Jonathan E. Kiechle More articles by this author Xinning Wang More articles by this author Shan Dong More articles by this author Steve S. Huang More articles by this author Warren D.W. Heston More articles by this author Lee E. Ponsky More articles by this author James P. Basilion More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...